Stemline Therapeutics, Inc. – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “Stemline Therapeutics, Inc. - Product Pipeline Review - 2012” provides data on the Stemline Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Stemline Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Stemline Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Current R&D Portfolio of Stemline Therapeutics, Inc.; Stemline Therapeutics, Inc. - Key Therapeutics; Stemline Therapeutics, Inc. - Pipeline Overview and Promising Molecules; Stemline Therapeutics, Inc. - News; Stemline Therapeutics, Inc. - Latest Updates; Stemline Therapeutics, Inc. - Pipeline; Stemline Therapeutics, Inc. - Discontinued/Dormant Projects
Summary
Global Market Direct’s pharmaceuticals report, “Stemline Therapeutics, Inc. - Product Pipeline Review - 2012” provides data on the Stemline Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Stemline Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Stemline Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Stemline Therapeutics, Inc. - Brief Stemline Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Stemline Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Stemline Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Stemline Therapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Stemline Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Stemline Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Stemline Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Stemline Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Stemline Therapeutics, Inc. and identify potential opportunities in those areas.
Current R&D Portfolio of Stemline Therapeutics, Inc.; Stemline Therapeutics, Inc. - Key Therapeutics; Stemline Therapeutics, Inc. - Pipeline Overview and Promising Molecules; Stemline Therapeutics, Inc. - News; Stemline Therapeutics, Inc. - Latest Updates; Stemline Therapeutics, Inc. - Pipeline; Stemline Therapeutics, Inc. - Discontinued/Dormant Projects
Stemline Therapeutics, Inc. Snapshot
Stemline Therapeutics, Inc. Overview
Key Information
Key Facts
Stemline Therapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
Stemline Therapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Stemline Therapeutics, Inc. – Pipeline Products Glance
Stemline Therapeutics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Stemline Therapeutics, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Stemline Therapeutics, Inc. – Drug Profiles
SL-101
Product Description
Mechanism of Action
R&D Progress
SL-201
Product Description
Mechanism of Action
R&D Progress
SL-202
Product Description
Mechanism of Action
R&D Progress
SL-301
Product Description
Mechanism of Action
R&D Progress
SL-302
Product Description
Mechanism of Action
R&D Progress
SL-401
Product Description
Mechanism of Action
R&D Progress
SL-501
Product Description
Mechanism of Action
R&D Progress
SL-601
Product Description
Mechanism of Action
R&D Progress
SL-701
Product Description
Mechanism of Action
R&D Progress
Stemline Therapeutics, Inc. – Pipeline Analysis
Stemline Therapeutics, Inc. – Pipeline Products by Therapeutic Class
Stemline Therapeutics, Inc. – Pipeline Products By Target
Stemline Therapeutics, Inc. – Pipeline Products By Mechanism of Action
Stemline Therapeutics, Inc. – Recent Pipeline Updates
Stemline Therapeutics, Inc. - Dormant Projects
Stemline Therapeutics, Inc. – Locations And Subsidiaries
Head Office
Stemline Therapeutics, Inc., Recent Developments
Stemline Therapeutics, Inc.- Press Release
Apr 18, 2012: Stemline Therapeutics Presents Trial Results Of Two Clinical Studies Of SL-701 At Annual Meeting Of American Association For Cancer Research
Dec 04, 2009: Stemline Therapeutics Announces Poster Presenting Of SL-401 Against Chronic Myeloid Leukemia (CML) At The 51st Annual Meeting Of The American Society Of Hematology (ASH)
Dec 04, 2009: Stemline Therapeutics To Present SL-501 Against Chronic Myeloid Leukemia At The 51st Annual Meeting of the American Society of Hematology
Nov 30, 2009: Stemline Therapeutics Expands Clinical Oncology Program Directed At Cancer Stem Cells With Addition Of M.D. Anderson Cancer Center
Financial Deals Landscape
Stemline Therapeutics, Inc., Deals Summary
Stemline Therapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Stemline Therapeutics Raises $0.74 Million In Venture Financing
Stemline Therapeutics Secures $12.5 Million In Financing
Partnerships
Stemline Therapeutics Enters Into Co-Development Agreement With M.D. Anderson Cancer Center
Xerion Pharma Enters Into An Agreement With Stemline Therapeutics
Licensing Agreements
University Of Cambridge Enters Into Licensing Agreement With Stemline Therapeutics
Stemline Therapeutics Enters Into Licensing Agreement With University Of Pittsburgh
Stemline Therapeutics Enters Into Licensing Agreement With Scott & White Cancer Research Institute
Equity Offering
Stemline Therapeutics Files Registration Statement For IPO Of Shares For $50 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Stemline Therapeutics, Inc., Key Information
Stemline Therapeutics, Inc., Key Facts
Stemline Therapeutics, Inc. – Pipeline by Indication, 2012
Stemline Therapeutics, Inc. – Pipeline by Stage of Development, 2012
Stemline Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012
Stemline Therapeutics, Inc. – Phase II, 2012
Stemline Therapeutics, Inc. – Pre-Clinical, 2012
Stemline Therapeutics, Inc. – Discovery, 2012
Stemline Therapeutics, Inc. – Pipeline By Therapeutic Class, 2012
Stemline Therapeutics, Inc. - Pipeline By Target, 2012
Stemline Therapeutics, Inc. – Pipeline Products By Mechanism of Action, 2012
Stemline Therapeutics, Inc. – Recent Pipeline Updates, 2012
Stemline Therapeutics, Inc. - Dormant Developmental Projects,2012
Stemline Therapeutics, Inc., Deals Summary
Stemline Therapeutics Raises $0.74 Million In Venture Financing
Stemline Therapeutics Secures $12.5 Million In Financing
Stemline Therapeutics Enters Into Co-Development Agreement With M.D. Anderson Cancer Center
Xerion Pharma Enters Into An Agreement With Stemline Therapeutics
University Of Cambridge Enters Into Licensing Agreement With Stemline Therapeutics
Stemline Therapeutics Enters Into Licensing Agreement With University Of Pittsburgh
Stemline Therapeutics Enters Into Licensing Agreement With Scott & White Cancer Research Institute
Stemline Therapeutics Files Registration Statement For IPO Of Shares For $50 Million
LIST OF FIGURES
Stemline Therapeutics, Inc. – Pipeline by Indication, 2012
Stemline Therapeutics, Inc. – Pipeline by Stage of Development, 2012
Stemline Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012
Stemline Therapeutics, Inc. – Pipeline By Therapeutic Class, 2012
Stemline Therapeutics, Inc. - Pipeline By Target, 2012
Stemline Therapeutics, Inc. - Pipeline Products By Mechanism of Action, 2012
Stemline Therapeutics, Inc. Overview
Key Information
Key Facts
Stemline Therapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
Stemline Therapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Stemline Therapeutics, Inc. – Pipeline Products Glance
Stemline Therapeutics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Stemline Therapeutics, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Stemline Therapeutics, Inc. – Drug Profiles
SL-101
Product Description
Mechanism of Action
R&D Progress
SL-201
Product Description
Mechanism of Action
R&D Progress
SL-202
Product Description
Mechanism of Action
R&D Progress
SL-301
Product Description
Mechanism of Action
R&D Progress
SL-302
Product Description
Mechanism of Action
R&D Progress
SL-401
Product Description
Mechanism of Action
R&D Progress
SL-501
Product Description
Mechanism of Action
R&D Progress
SL-601
Product Description
Mechanism of Action
R&D Progress
SL-701
Product Description
Mechanism of Action
R&D Progress
Stemline Therapeutics, Inc. – Pipeline Analysis
Stemline Therapeutics, Inc. – Pipeline Products by Therapeutic Class
Stemline Therapeutics, Inc. – Pipeline Products By Target
Stemline Therapeutics, Inc. – Pipeline Products By Mechanism of Action
Stemline Therapeutics, Inc. – Recent Pipeline Updates
Stemline Therapeutics, Inc. - Dormant Projects
Stemline Therapeutics, Inc. – Locations And Subsidiaries
Head Office
Stemline Therapeutics, Inc., Recent Developments
Stemline Therapeutics, Inc.- Press Release
Apr 18, 2012: Stemline Therapeutics Presents Trial Results Of Two Clinical Studies Of SL-701 At Annual Meeting Of American Association For Cancer Research
Dec 04, 2009: Stemline Therapeutics Announces Poster Presenting Of SL-401 Against Chronic Myeloid Leukemia (CML) At The 51st Annual Meeting Of The American Society Of Hematology (ASH)
Dec 04, 2009: Stemline Therapeutics To Present SL-501 Against Chronic Myeloid Leukemia At The 51st Annual Meeting of the American Society of Hematology
Nov 30, 2009: Stemline Therapeutics Expands Clinical Oncology Program Directed At Cancer Stem Cells With Addition Of M.D. Anderson Cancer Center
Financial Deals Landscape
Stemline Therapeutics, Inc., Deals Summary
Stemline Therapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Stemline Therapeutics Raises $0.74 Million In Venture Financing
Stemline Therapeutics Secures $12.5 Million In Financing
Partnerships
Stemline Therapeutics Enters Into Co-Development Agreement With M.D. Anderson Cancer Center
Xerion Pharma Enters Into An Agreement With Stemline Therapeutics
Licensing Agreements
University Of Cambridge Enters Into Licensing Agreement With Stemline Therapeutics
Stemline Therapeutics Enters Into Licensing Agreement With University Of Pittsburgh
Stemline Therapeutics Enters Into Licensing Agreement With Scott & White Cancer Research Institute
Equity Offering
Stemline Therapeutics Files Registration Statement For IPO Of Shares For $50 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Stemline Therapeutics, Inc., Key Information
Stemline Therapeutics, Inc., Key Facts
Stemline Therapeutics, Inc. – Pipeline by Indication, 2012
Stemline Therapeutics, Inc. – Pipeline by Stage of Development, 2012
Stemline Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012
Stemline Therapeutics, Inc. – Phase II, 2012
Stemline Therapeutics, Inc. – Pre-Clinical, 2012
Stemline Therapeutics, Inc. – Discovery, 2012
Stemline Therapeutics, Inc. – Pipeline By Therapeutic Class, 2012
Stemline Therapeutics, Inc. - Pipeline By Target, 2012
Stemline Therapeutics, Inc. – Pipeline Products By Mechanism of Action, 2012
Stemline Therapeutics, Inc. – Recent Pipeline Updates, 2012
Stemline Therapeutics, Inc. - Dormant Developmental Projects,2012
Stemline Therapeutics, Inc., Deals Summary
Stemline Therapeutics Raises $0.74 Million In Venture Financing
Stemline Therapeutics Secures $12.5 Million In Financing
Stemline Therapeutics Enters Into Co-Development Agreement With M.D. Anderson Cancer Center
Xerion Pharma Enters Into An Agreement With Stemline Therapeutics
University Of Cambridge Enters Into Licensing Agreement With Stemline Therapeutics
Stemline Therapeutics Enters Into Licensing Agreement With University Of Pittsburgh
Stemline Therapeutics Enters Into Licensing Agreement With Scott & White Cancer Research Institute
Stemline Therapeutics Files Registration Statement For IPO Of Shares For $50 Million
LIST OF FIGURES
Stemline Therapeutics, Inc. – Pipeline by Indication, 2012
Stemline Therapeutics, Inc. – Pipeline by Stage of Development, 2012
Stemline Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012
Stemline Therapeutics, Inc. – Pipeline By Therapeutic Class, 2012
Stemline Therapeutics, Inc. - Pipeline By Target, 2012
Stemline Therapeutics, Inc. - Pipeline Products By Mechanism of Action, 2012